Market Analysis - Counseling Psychology 2017
2nd International Conference on Counselling Psychology 2017 welcomes attendees, presenters, and exhibitors from all over the world to Osaka, Japan. We are delighted to invite you all to attend and register for the International Conference on Psychological Abnormalities and Counseling psychology which is going to be held during October 16-17, 2017 Osaka, Japan.
The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. Our conference will provide you with exciting opportunities and international platform for hands-on learning and networking with colleagues, and communication with industry partners.
Consumption of Anti- Depressants:
The new Antidepressants and psychiatric drugs in the Japan market, is significantly less comparatively than
Western countries. One of the main preferences to anti-depressants coming to the market is that, the Medical
Insurance system in Japan is national, and the authorities need to contain a potentially explosive market for
some drugs like anti-depressants that could be used or abused by different persons in various forms of distress
and depression. Although large epidemiological studies have not been done in Japan, it is thought that nearly
6 million Japanese suffer from depression and distress, with a lifetime prevalence of 17 to 21.3%, which is
followed to be seen in few countries like
Australia – 9.6%
United States – 8.8%
Africa – 15.4%
Japan – 32%
China – 12.6%
Other Countries – 21.6%
The market has seen the entry of the selective reuptake serotonin inhibitors (SSRIs) fluvoxamine, paroxetine
(Paxil-GSK), sertraline and the SNRI milnacipran, other antidepressantsincluding citalopram , Celexa
(Forest), fluoxetine, venlafaxine, mirtazapine and others are either still under investigation in Japan or have
dropped their pursuit on gaining entry into the Japan market. Although none of the anti-depressants present
in the Japan market have been studied using the placebo controls, this had begun to change since 2000s.
Prior clinical developments have placed a new drug against a drug already present in the market using a noninferiority
method of comparison which is known to be a subject to placebo effects, e.g. depressive symptoms
lifting due to effects other than pharmacologic drug effect.
Sertraline received an approval in April 2006 after nearly 15 years of clinical trial development in Japan.
The Japan algorithm for mood disorders does not include many of the post-tricyclic anti-depressants, were
used as first-line antidepressants in the Western countries for almost two decades, and recent studies are still
comparing SSRIs and tricyclic antidepressants, even though tricyclics are clearly 2nd or 3rd line treatments
in the West. Organ on International and Meiji Seika have filed an application for approval of mirtazapine in
Japan, a drug on the market in many Western countries since 1994.
Citalopram (Lund beck), an SSRI on the market since the late 1980s is not available in Japan, however on
April 22, 2011 escitalopram (the S-isomer enantiomer of citalopram), was approved for use in Japan. There
is little news, however, on the status of bupropion (Glaxo Smith-Kline), used widely in Western countries
since the early 1990s and long in clinical trials in Japan.